CFO John Sakys Sells Shares of Mesa Laboratories
John Sakys, CFO of Mesa Laboratories, sold over 1,200 shares in a planned transaction.
Key Points
- John Sakys, CFO of Mesa Laboratories, sold 1,223 shares at $101.27 each on June 16, 2026, in a planned transaction.
- Mesa Laboratories, Inc. has a market cap of about $550.7 million and a P/E ratio of 82.38, trading near $99.68.
- Peers like Long Path Partners and Boston Partners adjusted their holdings, with Long Path Partners increasing by 178,360 shares.
John Sakys, Chief Financial Officer of Mesa Laboratories, Inc. (NasdaqGS: MLAB), sold 1,223 shares on June 16, 2026. The shares were sold at an average price of $101.27 each, amounting to a total value of $123,853.21. This transaction was part of a planned sale.
Insider Buying and Selling at Mesa Laboratories, Inc.
In addition to John Sakys, other executives at Mesa Laboratories also made transactions recently. On June 16, 2026, Brian David Archbold, Senior Vice President of Operations, sold 1,151 shares at the same price of $101.27. Lyndsey Elizabeth Crennen, Chief Accounting Officer, sold 118 shares on the same day. These transactions were also planned. On June 15, 2026, John Sakys purchased 2,717 shares at $104.08 in an unplanned transaction.
Other Institutional Activity in Mesa Laboratories
Several institutional investors have adjusted their positions in Mesa Laboratories recently. Long Path Partners LP increased its holdings by 178,360 shares, bringing its total to 405,583 shares valued at approximately $35.86 million. Boston Partners also added 55,335 shares, now holding 268,711 shares worth about $23.76 million. Conversely, BlackRock, Inc. reduced its stake by 4,815 shares, leaving it with 393,851 shares valued at $34.82 million.
Mesa Laboratories Stock Snapshot
Shares of Mesa Laboratories, Inc. currently trade near $99.68. The company has a market cap of approximately $550.7 million and a P/E ratio of 82.38. Its forward P/E is 8.12. The stock's 52-week range is between $55.45 and $113.99, with a 50-day moving average of $101.95 and a 200-day moving average of $84.68. Mesa Laboratories has a beta of 0.927, indicating moderate volatility.
Recent Earnings
Mesa Laboratories reported revenue of $249.13 million, reflecting a growth of 2.6%. The company achieved a net margin of 2.694% and a return on equity of 3.879%. Earnings per share stood at $1.21. The next earnings report is expected on August 5, 2026.
Dividend
Mesa Laboratories pays an annual dividend of $0.64 per share, yielding 0.64%. The dividend payout ratio is 52.89%, indicating the portion of earnings distributed to shareholders.
Analysts Set New Price Targets
On February 4, 2026, Wells Fargo maintained its "hold" rating for Mesa Laboratories with a price target of $94. The consensus among analysts is a "hold" recommendation, with an average target price of $112 based on two analyst opinions.
About Mesa Laboratories
Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, designs and manufactures life sciences tools and quality control products. The company serves a broad range of industries, including pharmaceutical, medical device, and healthcare. Its segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Mesa Laboratories operates globally, offering products like sterilization indicators, genetic analysis tools, and calibration systems.
Bottom Line
John Sakys' recent planned sale of Mesa Laboratories shares is part of routine insider activity. Investors often watch such transactions for insights, although they don't necessarily indicate the executive's outlook on the company. Mesa Laboratories continues to be a notable player in the scientific and technical instruments sector, with ongoing institutional interest and analyst coverage.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.